Prostate Cancer Facts

Prostate Cancer Treatment Options

Seed Implants

Prostatectomy Facts

Proton Beam Therapy

Frequently Asked Questions

Talk to an expert

Appointments

 

 

PubMed Publications



PubMed


PubMed comprises more than 21 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

 

Verticle Divider

 

PubMed PUBLICATIONS CONTINUED

 

 

1. Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. Carpenter TJ, Forsythe K, Kao J, Stone NN, Stock RG.Brachytherapy. 2010 Nov 22. [Epub ahead of print]PMID: 21106445 [PubMed - as supplied by publisher] Related citations

2. Counterpoint: there is a dose-response relationship in the low-dose rate brachytherapy management of prostate cancer. Stock RG.Brachytherapy. 2010 Oct-Dec;9(4): 293-6; discussion 299. Epub 2010 Sep 15. No abstract available. PMID: 20833593 [PubMed - in process] Related citations

3. Association between number of cell phone contracts and brain tumor incidence in nineteen U.S. States. Lehrer S, Green S, Stock RG.J Neurooncol. 2010 Jun 30. [Epub ahead of print] PMID: 20589524 [PubMed - as supplied by publisher] Related citations 

4. Current topics in the treatment of prostate cancer with low-dose-rate brachytherapy. Stock RG, Stone NN.Urol Clin North Am. 2010 Feb;37(1):83-96, Table of Contents. Review.PMID: 20152522 [PubMed - indexed for MEDLINE] Related citations

5. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Burri RJ, Stone NN, Unger P, Stock RG.Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1338-44.PMID: 20138442 [PubMed - indexed for MEDLINE] Related citations

6. Young men have equivalent biochemical outcomes compared with older men after treatment with brachytherapy for prostate cancer. Burri RJ, Ho AY, Forsythe K, Cesaretti JA, Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1315-21. Epub 2010 Jan 13.PMID: 20044216 [PubMed - indexed for MEDLINE] Related citations

7. Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy? Stone NN, Marshall DT, Stone JJ, Cesaretti JA, Stock RG.J Urol. 2010 Feb;183(2):634-9. Epub 2009 Dec 16.PMID: 20018308 [PubMed - indexed for MEDLINE] Related citations

8. Impact of hormonal therapy on intermediate risk prostate cancer treated with combination brachytherapy and external beam irradiation. Stock RG, Yalamanchi S, Hall SJ, Stone NN.J Urol. 2010 Feb;183(2):546-50. Epub 2009 Dec 14. Erratum in: J Urol. 2010 Apr;183(4):1650. Yamalachi, Swati [corrected to Yalamanchi, Swati]. PMID: 20006854 [PubMed - indexed for MEDLINE] Related citations

9. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity? Stone NN, Cesaretti JA, Rosenstein B, Stock RG.Brachytherapy. 2010 Apr-Jun;9(2):114-8. Epub 2009 Oct 30.PMID: 19879812 [PubMed - indexed for MEDLINE ]Related citations

10. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. Stone NN, Stock RG, Cesaretti JA, Unger P.Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):355-60. Epub 2009 Jul 23.PMID: 19632069 [PubMed - indexed for MEDLINE] Related citations

11. Postoperative nomogram predicting the 9-year probability of prostate cancer recurrence after permanent prostate brachytherapy using radiation dose as a prognostic variable. Potters L, Roach M 3rd, Davis BJ, Stock RG, Ciezki JP, Zelefsky MJ, Stone NN, Fearn PA, Yu C, Shinohara K, Kattan MW.Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1061-5. Epub 2009 Jun 18.PMID: 19540064 [PubMed - indexed for MEDLINE] Related citations

12. Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases: acute toxicity and preliminary response. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo YC, Huang D, Chen SH, Cesaretti JA.Cancer. 2009 Aug 1;115(15):3571-80.PMID: 19536893 [PubMed - indexed for MEDLINE] Free Article Related citations

13. Outcomes for patients with high-grade prostate cancer treated with a combination of brachytherapy, external beam radiotherapy and hormonal therapy. Stock RG, Cesaretti JA, Hall SJ, Stone NN.BJU Int. 2009 Dec;104(11):1631-6. Epub 2009 Jun 2.PMID: 19493260 [PubMed - indexed for MEDLINE] Related citations

14. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy. Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. Epub 2009 Mar 14.PMID: 19289266 [PubMed - indexed for MEDLINE] Related citations

15. Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy.Stock RG, Klein TJ, Cesaretti JA, Stone NN.Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):753-8. Epub 2008 Dec 10.PMID: 19084351 [PubMed - indexed for MEDLINE] Related citations 

16. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R.J Oral Maxillofac Surg. 2009 Jan;67(1):159-61.PMID: 19070762 [PubMed - indexed for MEDLINE] Related citations

17. Counterpoint: High-risk prostate cancer: the case for combination brachytherapy and external beam irradiation. Stock RG.Brachytherapy. 2008 Oct-Dec;7(4):280-2; discussion 283. No abstract available. PMID: 18928921 [PubMed - indexed for MEDLINE] Related citations

18. There is no correlation between erectile dysfunction and dose to penile bulb and neurovascular bundles following real-time low-dose-rate prostate brachytherapy. Solan AN, Cesaretti JA, Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2009 Apr 1;73(5):1468-74. Epub 2008 Oct 14.PMID: 18922652 [PubMed - indexed for MEDLINE] Related citations

19. Effect of family history on outcomes in patients treated with definitive brachytherapy for clinically localized prostate cancer. Peters CA, Stock RG, Blacksburg SR, Stone NN.Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):24-9. Epub 2008 Aug 7.PMID: 18692325 [PubMed - indexed for MEDLINE] Related citations

20. Distant and local recurrence in patients with biochemical failure after prostate brachytherapy. Stock RG, Cesaretti JA, Unger P, Stone NN.Brachytherapy. 2008 Jul-Sep;7(3):217-22.PMID: 18635024 [PubMed - indexed for MEDLINE] Related citations 

21. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG.Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):341-6. Epub 2008 Jul 1.PMID: 18597953 [PubMed - indexed for MEDLINE] Related citations

22. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS.Radiat Res. 2008 Jul;170(1):49-59.PMID: 18582155 [PubMed - indexed for MEDLINE] Related citations

23. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Sep;106(3):389-91. Epub 2008 Jun 13.PMID: 18554944 [PubMed - indexed for MEDLINE] Related citations

24. (125)I monotherapy using D90 implant doses of 180 Gy or greater. Kao J, Stone NN, Lavaf A, Dumane V, Cesaretti JA, Stock RG.Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):96-101. Epub 2007 Nov 5.PMID: 17980505 [PubMed - indexed for MEDLINE] Related citations

25. Brachytherapy for the treatment of prostate cancer. Cesaretti JA, Stone NN, Skouteris VM, Park JL, Stock RG.Cancer J. 2007 Sep-Oct;13(5):302-12. Review.PMID: 17921729 [PubMed - indexed for MEDLINE] Related citations

26. TGFB1 single nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. Peters CA, Stock RG, Cesaretti JA, Atencio DP, Peters S, Burri RJ, Stone NN, Ostrer H, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):752-9. Epub 2007 Aug 8.PMID: 17689884 [PubMed - indexed for MEDLINE] Related citations

27. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Fearn PA, Kattan MW, Stock RG.Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1472-7. Epub 2007 Aug 6.PMID: 17689026 [PubMed - indexed for MEDLINE] Related citations

28. Effect of low dose-rate prostate brachytherapy on the sexual health of men with optimal sexual function before treatment: analysis at > or = 7 years of follow-up. Cesaretti JA, Kao J, Stone NN, Stock RG.BJU Int. 2007 Aug;100(2):362-7.PMID: 17617140 [PubMed - indexed for MEDLINE] Related citations 

29. Possession of ATM sequence variants as predictor for late normal tissue responses in breast cancer patients treated with radiotherapy. Ho AY, Fan G, Atencio DP, Green S, Formenti SC, Haffty BG, Iyengar P, Bernstein JL, Stock RG, Cesaretti JA, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):677-84. Epub 2007 May 22.PMID: 17517479 [PubMed - indexed for MEDLINE] Related citations 

30. A genetically determined dose-volume histogram predicts for rectal bleeding among patients treated with prostate brachytherapy. Cesaretti JA, Stock RG, Atencio DP, Peters SA, Peters CA, Burri RJ, Stone NN, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1410-6. Epub 2007 May 9.PMID: 17490827 [PubMed - indexed for MEDLINE] Related citations

31. Patterns of local failure following prostate brachytherapy. Stone NN, Stock RG, White I, Unger P.J Urol. 2007 May;177(5):1759-63; duscussion 1763-4.PMID: 17437808 [PubMed - indexed for MEDLINE] Related citations 

32. Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years. Stone NN, Stock RG.Urology. 2007 Feb;69(2):338-42.PMID: 17320674 [PubMed - indexed for MEDLINE] Related citations

33. The effect of brachytherapy, external beam irradiation and hormonal therapy on prostate volume. Stone NN, Stock RG.J Urol. 2007 Mar;177(3):925-8.PMID: 17296377 [PubMed - indexed for MEDLINE] Related citations

34. Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer. Ho AY, Burri RJ, Jennings GT, Stone NN, Cesaretti JA, Stock RG.Brachytherapy. 2007 Jan-Mar;6(1):38-43.PMID: 17284384 [PubMed - indexed for MEDLINE] Related citations

35. Assessment of postbrachytherapy sexual function: a comparison of the IIEF-5 and the MSEFS. Zagar TM, Stock RG, Cesaretti JA, Stone NN.Brachytherapy. 2007 Jan-Mar;6(1):26-33.PMID: 17284382 [PubMed - indexed for MEDLINE] Related citations

36. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M 3rd, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC.Brachytherapy. 2007 Jan-Mar;6(1):2-8.PMID: 17284379 [PubMed - indexed for MEDLINE] Related citations

37. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation. Lehrer S, Cesaretti J, Stone NN, Stock RG.BJU Int. 2006 Nov;98(5):979-81.PMID: 17034599 [PubMed - indexed for MEDLINE] Related citations 

38. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Stock RG, Ho A, Cesaretti JA, Stone NN.Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):389-94.PMID: 16965991 [PubMed - indexed for MEDLINE] Related citations

39. Low-dose rate prostate brachytherapy is well tolerated in patients with a history of inflammatory bowel disease. Peters CA, Cesaretti JA, Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):424-9. Epub 2006 Aug 2.PMID: 16887295 [PubMed - indexed for MEDLINE] Related citations

40. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):646-55. PMID: 16751059 [PubMed - indexed for MEDLINE]R elated citations

41. High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer: The case for low-dose-rate monotherapy. Stock RG.Brachytherapy. 2006 Jan-Mar;5(1):5-6; discussion 8. No abstract available. PMID: 16563989 [PubMed - indexed for MEDLINE] Related citations

42. ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy. Andreassen CN, Overgaard J, Alsner J, Overgaard M, Herskind C, Cesaretti JA, Atencio DP, Green S, Formenti SC, Stock RG, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):776-83. Epub 2005 Dec 9. PMID: 16338099 [PubMed - indexed for MEDLINE] Related citations

43. Disease-specific survival following the brachytherapy management of prostate cancer. Stock RG, Cesaretti JA, Stone NN.Int J Radiat Oncol Biol Phys. 2006 Mar 1;64(3):810-6. Epub 2005 Nov 23. PMID: 16309852 [PubMed - indexed for MEDLINE] Related citations

44. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):527-33. Epub 2005 Oct 19.PMID: 16242258 [PubMed - indexed for MEDLINE] Related citations

45. Critical organ dosimetry in permanent seed prostate brachytherapy: defining the organs at risk. Crook JM, Potters L, Stock RG, Zelefsky MJ.Brachytherapy. 2005;4(3):186-94.PMID: 16182218 [PubMed - indexed for MEDLINE] Related citations

46. Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer. Lehrer S, Diamond EJ, Stone NN, Stock RG.BJU Int. 2005 Aug;96(3):328-9.PMID: 16042724 [PubMed - indexed for MEDLINE] Related citations

47. Reduction of pulmonary migration of permanent interstitial sources in patients undergoing prostate brachytherapy. Stone NN, Stock RG.Urology. 2005 Jul;66(1):119-23.PMID: 15992909 [PubMed - indexed for MEDLINE] Related citations

48. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG.BJU Int. 2005 May;95(7):961-2.PMID: 15839913 [PubMed - indexed for MEDLINE] Related citations

49. Urinary morbidity and incontinence following transurethral resection of the prostate after brachytherapy. Kollmeier MA, Stock RG, Cesaretti J, Stone NN.J Urol. 2005 Mar;173(3):808-12. Review.PMID: 15711274 [PubMed - indexed for MEDLINE] Related citations

50. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. Stone NN, Stock RG, Unger P.J Urol. 2005 Mar;173(3):803-7.PMID: 15711273 [PubMed - indexed for MEDLINE] Related citations

51. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Cesaretti JA, Stock RG, Lehrer S, Atencio DA, Bernstein JL, Stone NN, Wallenstein S, Green S, Loeb K, Kollmeier M, Smith M, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):196-202.PMID: 15629612 [PubMed - indexed for MEDLINE] Related citations

52. Prostate cancer in a large prostate is associated with a decreased prostate specific antigen failure rate after brachytherapy. Lehrer S, Stone NN, Stock RG.J Urol. 2005 Jan;173(1):79-81.PMID: 15592033 [PubMed - indexed for MEDLINE]Related citations

53. Serum interleukin-8 is elevated in men with prostate cancer and bone metastases.Lehrer S, Diamond EJ, Mamkine B, Stone NN, Stock RG.Technol Cancer Res Treat. 2004 Oct;3(5):411.PMID: 15453805 [PubMed - indexed for MEDLINE] Free Article Related citations

54. Does prior transurethral resection of prostate compromise brachytherapy quality: a dosimetric analysis. Cesaretti JA, Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):648-53.PMID: 15380602 [PubMed - indexed for MEDLINE] Related citations

55. Combined modality treatment in the management of high-risk prostate cancer. Stock RG, Cahlon O, Cesaretti JA, Kollmeier MA, Stone NN.Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1352-9.PMID: 15275720 [PubMed - indexed for MEDLINE] Related citations

56. Prostate gland motion and deformation caused by needle placement during brachytherapy. Stone NN, Roy J, Hong S, Lo YC, Stock RG.Brachytherapy. 2002;1(3):154-60.PMID: 15090279 [PubMed - indexed for MEDLINE] Related citations

57. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer. Stock RG, Stone NN.Brachytherapy. 2002;1(1):2-10. Review.PMID: 15062181 [PubMed - indexed for MEDLINE] Related citations 

58. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms. Stock RG, Stone NN, Dahlal M, Lo YC.Brachytherapy. 2002;1(2):83-9.PMID: 15062175 [PubMed - indexed for MEDLINE] Related citations

59. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy. Stone NN, Stock RG.Brachytherapy. 2003;2(1):32-9.PMID: 15062161 [PubMed - indexed for MEDLINE] Related citations

60. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy. Stone NN, Hong S, Lo YC, Howard V, Stock RG.Brachytherapy. 2003;2(1):17-25.PMID: 15062159 [PubMed - indexed for MEDLINE] Related citations 

61. The role of hormonal therapy in prostate brachytherapy. Point. Stock RG.Brachytherapy. 2003;2(1):1-2. No abstract available. PMID: 15062156 [PubMed - indexed for MEDLINE] Related citations

62. Influence of prostate volume on dosimetry results in real-time 125I seed implantation. McNeely LK, Stone NN, Presser J, Chircus JH, Stock RG.Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):292-9.PMID: 14697451 [PubMed - indexed for MEDLINE] Related citations

63. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Kollmeier MA, Stock RG, Stone N.Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.PMID: 14529768 [PubMed - indexed for MEDLINE] Related citations

64. Putative protein markers in the sera of men with prostatic neoplasms. Lehrer S, Roboz J, Ding H, Zhao S, Diamond EJ, Holland JF, Stone NN, Droller MJ, Stock RG.BJU Int. 2003 Aug;92(3):223-5.PMID: 12887471 [PubMed - indexed for MEDLINE] Related citations

65. Elevated serum triiodothyronine (t3) in Ashkenazi Jewish prostate cancer patients carrying the I1307k allele of the APC (adenopolyposis coli) gene. Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG, Stone M, Bajwa A, Kornreich R.Urol Oncol. 2003 Mar-Apr;21(2):101-4.PMID: 12856637 [PubMed - indexed for MEDLINE] Related citations

66. Urinary symptom flare following I-125 prostate brachytherapy. Cesaretti JA, Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1085-92.PMID: 12829146 [PubMed - indexed for MEDLINE] Related citations

67. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Stock RG, Stone NN, Cesaretti JA.Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):448-53.PMID: 12738319 [PubMed - indexed for MEDLINE] Related citations

68. Practical considerations in permanent brachytherapy for localized adenocarcinoma of the prostate. Stone NN, Stock RG.Urol Clin North Am. 2003 May;30(2):351-62.PMID: 12735510 [PubMed - indexed for MEDLINE] Related citations 

69. Association between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer. Lehrer S, Diamond EJ, Bajwa AM, Kornreich R, Stagger S, Stone NN, Droller MJ, Stock RG.Prostate Cancer Prostatic Dis. 2001;4(4):232-234.PMID: 12497024 [PubMed - as supplied by publisher] Free Article Related citations

70. Re: Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer .Lehrer S, Diamond EJ, Droller MJ, Stone NN, Stock RG.J Natl Cancer Inst. 2002 Dec 18;94(24):1893; author reply 1893-4. No abstract available. PMID: 12488486 [PubMed - indexed for MEDLINE] Free Article Related citations

71. Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer. Lehrer S, Stone NN, Droller MJ, Stock RG.Urol Oncol. 2002 Mar-Apr;7(2):73-6.PMID: 12474526 [PubMed - indexed for MEDLINE] Related citations

72. Serum triiodothyronine is increased in men with prostate cancer and benign prostatic hyperplasia. Lehrer S, Diamond EJ, Stone NN, Droller MJ, Stock RG.J Urol. 2002 Dec;168(6):2431-3.PMID: 12441933 [PubMed - indexed for MEDLINE] Related citations

73. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.Br J Cancer. 2002 Sep 23;87(7):726-8.PMID: 12232754 [PubMed - indexed for MEDLINE] Free PMC Article Free textRelated citations

74. Permanent seed implantation for localized adenocarcinoma of the prostate. Stone NN, Stock RG.Curr Urol Rep. 2002 Jun;3(3):201-6. Review.PMID: 12084189 [PubMed - indexed for MEDLINE] Related citations

75. Importance of post-implant dosimetry in permanent prostate brachytherapy. Stock RG, Stone NN.Eur Urol. 2002 Apr;41(4):434-9. Review.PMID: 12074816 [PubMed - indexed for MEDLINE] Related citations

76. Complications following permanent prostate brachytherapy. Stone NN, Stock RG.Eur Urol. 2002 Apr;41(4):427-33. Review.PMID: 12074815 [PubMed - indexed for MEDLINE] Related citations

77. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Lee LN, Stock RG, Stone NN.Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):444-52.PMID: 11872291 [PubMed - indexed for MEDLINE] Related citations

78. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS.Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):606-13.PMID: 11849780 [PubMed - indexed for MEDLINE] Related citations

79. Increased serum insulin associated with increased risk of prostate cancer recurrence. Lehrer S, Diamond EJ, Stagger S, Stone NN, Stock RG.Prostate. 2002 Jan 1;50(1):1-3.PMID: 11757030 [PubMed - indexed for MEDLINE] Related citations

80. Screening breast cancer patients for ATM mutations and polymorphisms by using denaturing high-performance liquid chromatography. Atencio DP, Iannuzzi CM, Green S, Stock RG, Bernstein JL, Rosenstein BS.Environ Mol Mutagen. 2001;38(2-3):200-8.PMID: 11746755 [PubMed - indexed for MEDLINE] Related citations

81. Intraoperative planning and evaluation of permanent prostate brachytherapy: report of the American Brachytherapy Society. Nag S, Ciezki JP, Cormack R, Doggett S, DeWyngaert K, Edmundson GK, Stock RG, Stone NN, Yu Y, Zelefsky MJ; Clinical Research Committe, American Brachytherapy Society.Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1422-30.PMID: 11728703 [PubMed - indexed for MEDLINE] Related citations

82. Defining the risk of developing grade 2 proctitis following 125I prostate brachytherapy using a rectal dose-volume histogram analysis. Snyder KM, Stock RG, Hong SM, Lo YC, Stone NN.Int J Radiat Oncol Biol Phys. 2001 Jun 1;50(2):335-41.PMID: 11380219 [PubMed - indexed for MEDLINE] Related citations 

83. Penile erectile function after permanent radioactive seed implantation for treatment of prostate cancer. Stock RG, Kao J, Stone NN.J Urol. 2001 Feb;165(2):436-9.PMID: 11176391 [PubMed - indexed for MEDLINE] Related citations

84. Body mass, age, and the APC I1307K allele in Ashkenazi Jewish prostate cancer patients. Lehrer S, McCurdy LD, Stock RG, Kornreich R, Stone NN, Eng C.Cancer Genet Cytogenet. 2000 Oct 15;122(2):131-3.PMID: 11106824 [PubMed - indexed for MEDLINE] Related citations

85. Effects of neoadjuvant hormonal therapy on prostate biopsy results after (125)I and (103)Pd seed implantation. Stone NN, Stock RG, Unger P.Mol Urol. 2000 Fall;4(3):163-8;discussion 169-70.PMID: 11062370 [PubMed - indexed for MEDLINE] Related citations

86. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization. Stock RG, Stone NN, Kao J, Iannuzzi C, Unger P.Cancer. 2000 Oct 15;89(8):1829-34.PMID: 11042580 [PubMed - indexed for MEDLINE] Free Article Related citations

87. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Stock RG, Stone NN, Lo YC, Malhado N, Kao J, DeWyngaert JK.Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):899-906.PMID: 11020588 [PubMed - indexed for MEDLINE] Related citations

88. Biopsy results after real-time ultrasound-guided transperineal implants for stage T1-T2 prostate cancer. Stone NN, Stock RG, Unger P, Kao J.J Endourol. 2000 May;14(4):375-80.PMID: 10910155 [PubMed - indexed for MEDLINE] Related citations 

89. Neoadjuvant Hormonal Therapy Improves the Outcomes of Patients Undergoing Radioactive Seed Implantation for Localized Prostate Cancer. Stone NN, Stock RG.Mol Urol. 1999;3(3):239-244.PMID: 10851329 [PubMed - as supplied by publisher] Related citations

90. Use of radioimmunoscintigraphy with indium-111-labeled CYT-356 (ProstaScint) scan for evaluation of patients for salvage brachytherapy. Fang DX, Stock RG, Stone NN, Krynyckyi BR, Kim CK, Machac J.Tech Urol. 2000 Jun;6(2):146-50.PMID: 10798816 [PubMed - indexed for MEDLINE] Related citations

91. Prior transurethral resection does not increase morbidity following real-time ultrasound-guided prostate seed implantation. Stone NN, Ratnow ER, Stock RG.Tech Urol. 2000 Jun;6(2):123-7.PMID: 10798813 [PubMed - indexed for MEDLINE] Related citations

92. Dynamic cystography can replace cystoscopy following prostate seed implantation. Stone NN, Stock RG.Tech Urol. 2000 Jun;6(2):112-6.PMID: 10798811 [PubMed - indexed for MEDLINE] Related citations

93. Intraoperative dosimetric representation of the real-time ultrasound-guided prostate implant. Stock RG, Stone NN, Lo YC.Tech Urol. 2000 Jun;6(2):95-8.PMID: 10798807 [PubMed - indexed for MEDLINE] Related citations

94. Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3): dosimetic analysis of implant quality. Stone NN, Stock RG.Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1199-204.PMID: 10725632 [PubMed - indexed for MEDLINE] Related citations

95. Does prostate brachytherapy treat the seminal vesicles? A dose-volume histogram analysis of seminal vesicles in patients undergoing combined PD-103 prostate implantation and external beam irradiation. Stock RG, Lo YC, Gaildon M, Stone NN.Int J Radiat Oncol Biol Phys. 1999 Sep 1;45(2):385-9.PMID: 10487560 [PubMed - indexed for MEDLINE] Related citations

96. Permanent radioactive seed implantation in the treatment of prostate cancer. Stock RG, Stone NN.Hematol Oncol Clin North Am. 1999 Jun;13(3):489-501. Review.PMID: 10432424 [PubMed - indexed for MEDLINE] Related citations

97. Prostate brachytherapy: treatment strategies. Stone NN, Stock RG.J Urol. 1999 Aug;162(2):421-6.PMID: 10411050 [PubMed - indexed for MEDLINE] Related citations

98. Rectal cancer and inflammatory bowel disease: natural history and implications for radiation therapy. Green S, Stock RG, Greenstein AJ.Int J Radiat Oncol Biol Phys. 1999 Jul 1;44(4):835-40.PMID: 10386640 [PubMed - indexed for MEDLINE] Related citations

99. PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. Iannuzzi CM, Stock RG, Stone NN.Radiat Oncol Investig. 1999;7(1):30-5.PMID: 10030621 [PubMed - indexed for MEDLINE] Related citations

100. Laparoscopic pelvic lymph node dissection in the staging of prostate cancer. Stone NN, Stock RG.Mt Sinai J Med. 1999 Jan;66(1):26-30.PMID: 9989102 [PubMed - indexed for MEDLINE] Related citations

101. Does pelvic irradiation play a role in the management of prostate cancer? Stock RG, Ferrari AC, Stone NN.Oncology (Williston Park). 1998 Oct;12(10):1467-72; discussion 1472, 1475-6. Review.PMID: 9798200 [PubMed - indexed for MEDLINE] Related citations 

102. Perineural invasion and seminal vesicle involvement predict pelvic lymph node metastasis in men with localized carcinoma of the prostate. Stone NN, Stock RG, Parikh D, Yeghiayan P, Unger P.J Urol. 1998 Nov;160(5):1722-6.PMID: 9783940 [PubMed - indexed for MEDLINE] Related citations

103. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. Terk MD, Stock RG, Stone NN.J Urol. 1998 Oct;160(4):1379-82. Review.PMID: 9751358 [PubMed - indexed for MEDLINE] Related citations

104. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M.Br J Cancer. 1998 Sep;78(6):771-3.PMID: 9743298 [PubMed - indexed for MEDLINE] Free PMC Article Free textRelated citations

105. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland. Desai J, Stock RG, Stone NN, Iannuzzi C, DeWyngaert JK.Radiat Oncol Investig. 1998;6(3):135-41.PMID: 9652912 [PubMed - indexed for MEDLINE] Related citations

106. A dose-response study for I-125 prostate implants. Stock RG, Stone NN, Tabert A, Iannuzzi C, DeWyngaert JK.Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):101-8.PMID: 9588923 [PubMed - indexed for MEDLINE] Related citations

107. A survey of physics and dosimetry practice of permanent prostate brachytherapy in the United States. Prete JJ, Prestidge BR, Bice WS, Friedland JL, Stock RG, Grimm PD.Int J Radiat Oncol Biol Phys. 1998 Mar 1;40(4):1001-5.PMID: 9531387 [PubMed - indexed for MEDLINE] Related citations

108. A survey of current clinical practice of permanent prostate brachytherapy in the United States. Prestidge BR, Prete JJ, Buchholz TA, Friedland JL, Stock RG, Grimm PD, Bice WS.Int J Radiat Oncol Biol Phys. 1998 Jan 15;40(2):461-5.PMID: 9457836 [PubMed - indexed for MEDLINE] Related citations

109. Enhanced radiosensitization with interferon-alpha-2b and cisplatin in the treatment of locally advanced cervical carcinoma. Stock RG, Dottino P, Jennings TS, Terk M, DeWyngaert JK, Beddoe AM, Cohen C.Gynecol Oncol. 1997 Dec;67(3):309-15.PMID: 9441780 [PubMed - indexed for MEDLINE] Related citations

110. The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy. Stock RG, Stone NN.Semin Surg Oncol. 1997 Nov-Dec;13(6):454-60.PMID: 9358593 [PubMed - indexed for MEDLINE] Related citations

111. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. Stone NN, Stock RG, Unger P.J Urol. 1997 Nov;158(5):1891-4.PMID: 9334624 [PubMed - indexed for MEDLINE] Related citations

112. A new technique for performing Syed-Neblett template interstitial implants for gynecologic malignancies using transrectal-ultrasound guidance. Stock RG, Chan K, Terk M, Dewyngaert JK, Stone NN, Dottino P.Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):819-25.PMID: 9128957 [PubMed - indexed for MEDLINE] Related citations

113. Seminal vesicle biopsy: accuracy and implications for staging of prostate cancer. Linzer DG, Stock RG, Stone NN, Ratnow R, Ianuzzi C, Unger P.Urology. 1996 Nov;48(5):757-61.PMID: 8911521 [PubMed - indexed for MEDLINE] Related citations

114. Patterns of spread in node-positive cervical cancer: the relationship between local control and distant metastases. Stock RG, Chen AS, Karasek K.Cancer J Sci Am. 1996 Sep-Oct;2(5):256-62.PMID: 9166542 [PubMed - indexed for MEDLINE] Related citations

115. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma. Stock RG, Stone NN, DeWyngaert JK, Lavagnini P, Unger PD.Cancer. 1996 Jun 1;77(11):2386-92.PMID: 8635111 [PubMed - indexed for MEDLINE] Related citations

116. Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Stock RG, Stone NN, Iannuzzi C.Int J Radiat Oncol Biol Phys. 1996 May 1;35(2):267-72.PMID: 8635932 [PubMed - indexed for MEDLINE] Related citations 

117. CT findings after laparoscopic pelvic lymph node dissection and transperineal radioactive seed implantation for prostatic carcinoma. Glajchen N, Shapiro RD, Stock RG, Stone NN, Ramos R.AJR Am J Roentgenol. 1996 May;166(5):1165-8.PMID: 8615263 [PubMed - indexed for MEDLINE] Free Article Related citations

118. Seminal vesicle biopsy and laparoscopic pelvic lymph node dissection: implications for patient selection in the radiotherapeutic management of prostate cancer. Stock RG, Stone NN, Ianuzzi C, Unger P.Int J Radiat Oncol Biol Phys. 1995 Nov 1;33(4):815-21.PMID: 7591888 [PubMed - indexed for MEDLINE] Related citations

119. Indications for seminal vesicle biopsy and laparoscopic pelvic lymph node dissection in men with localized carcinoma of the prostate. Stone NN, Stock RG, Unger P.J Urol. 1995 Oct;154(4):1392-6.PMID: 7658545 [PubMed - indexed for MEDLINE] Related citations

120. Locoregional therapies for early-stage prostate cancer. Stock RG.Oncology (Williston Park). 1995 Sep;9(9):803-11; discussion 815-6. Review.PMID: 8562323 [PubMed - indexed for MEDLINE] Related citations

121. Brachytherapy for prostate cancer: real-time three-dimensional interactive seed implantation. Stone NN, Stock RG.Tech Urol. 1995 Summer;1(2):72-80.PMID: 9118374 [PubMed - indexed for MEDLINE] Related citations 

122. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Stock RG, Stone NN, Wesson MF, DeWyngaert JK.Int J Radiat Oncol Biol Phys. 1995 Apr 30;32(1):219-25.PMID: 7721619 [PubMed - indexed for MEDLINE] Related citations

123. Node-positive cervical cancer: impact of pelvic irradiation and patterns of failure. Stock RG, Chen AS, Flickinger JC, Kalnicki S, Seski J.Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):31-6.PMID: 7995765 [PubMed - indexed for MEDLINE] Related citations

124. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Stock RG, Chen AS, Seski J.Gynecol Oncol. 1995 Jan;56(1):45-52.PMID: 7821847 [PubMed - indexed for MEDLINE] Related citations

125. The importance of brachytherapy technique in the management of primary carcinoma of the vagina. Stock RG, Mychalczak B, Armstrong JG, Curtin JP, Harrison LB.Int J Radiat Oncol Biol Phys. 1992;24(4):747-53.PMID: 1429100 [PubMed - indexed for MEDLINE] Related citations

126. Administrative ethics and conflicts of interest. Stock RG.Healthc Manage Forum. 1988 Summer;1(2):6-10. English, French. PMID: 10287874 [PubMed - indexed for MEDLINE] Related citations

127. Risk management committee of the board. Stock RG.Hosp Trustee. 1987 Mar-Apr;11(2):17-9. No abstract available. PMID: 10282084 [PubMed - indexed for MEDLINE] Related citations

128. Coping with constraints: planning for the future. Part 3. Stock RG, Herbert SW.Dimens Health Serv. 1983 Nov;60(11):33-4. No abstract available. PMID: 6360775 [PubMed - indexed for MEDLINE] Related citations

129. Coping with constraints: planning for the future. Part 3. Stock RG, Herbert SW.Hosp Trustee. 1983 Nov-Dec;7(6):16-7. No abstract available. PMID: 10264209 [PubMed - indexed for MEDLINE] Related citations

130. Coping with constraints: a six-step plan. Stock RG, Herbert SW.Dimens Health Serv. 1983 Sep;60(9):37-8. No abstract available. PMID: 6628866 [PubMed - indexed for MEDLINE] Related citations 

131. Coping with constraints: employee relations. Part 2. Stock RG, Herbert SW.Hosp Trustee. 1983 Sep-Oct;7(5):19-20. No abstract available. PMID: 10263143 [PubMed - indexed for MEDLINE] Related citations

132. Coping with constraints: a six-step plan. Part I. Stock RG, Herbert SW.Hosp Trustee. 1983 Jul-Aug;7(4):12-4. No abstract available. PMID: 10299250 [PubMed - indexed for MEDLINE] Related citations

© Richard G. Stock, M.D. | Site Map | Design: Merkley Marketing Group | Terms and Use | Privacy Policy